申请人:Taiho Pharmaceutical Co., Ltd.
公开号:US08304427B2
公开(公告)日:2012-11-06
Provided is a c-Met inhibitory antitumor agent which mitigates side effects by selectively affecting tumor cells in which c-Met is specifically expressed, having a formula (I) or its salt:
wherein each of R1 and R2 are independently a hydrogen atom, an optionally substituted C1-6 alkyl, C3-10 cycloalkyl, C6-14 aromatic hydrocarbon, or saturated or unsaturated heterocyclic group, or R1 and R2 may form, together with the nitrogen atom to which they are attached, an optionally substituted nitrogen-containing heterocyclic ring; R3 is a C1-6 alkyl group; and R4, R5, and R6, are independently a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkylamino group, an optionally substituted aromatic hydrocarbon group, or an optionally substituted saturated or unsaturated heterocyclic group, or R5 and R6 may form a ring together with the phenyl ring to which they are attached.
提供的是一种c-Met抑制剂的抗肿瘤药物,通过选择性地影响c-Met特异表达的肿瘤细胞来缓解副作用,其化学式为(I)或其盐:
其中,R1和R2各自独立地为氢原子、可选取代的C1-6烷基、C3-10环烷基、C6-14芳香烃或饱和或不饱和的杂环基,或R1和R2可以与它们连接的氮原子一起形成可选取代的含氮杂环环;R3为C1-6烷基;R4、R5和R6各自独立地为氢原子、卤素原子、可选取代的C1-6烷基、C1-6烷氧基、C1-6烷基氨基、可选取代的芳香烃基或可选取代的饱和或不饱和的杂环基,或R5和R6可以与它们连接的苯环一起形成环。